videoSlug

VideoSlug_VideoQuery

slug

VideoPageContentQuery

content

videos

query VideoSlug_VideoQuery(
  $videoSlug: String!
) {
  ...VideoPageContentQuery_1X4EH4
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment LatestVideos_Videos on Query {
  videos(first: 5, upcoming: false, order: {field: liveTime, direction: DESC}) {
    edges {
      node {
        id
        title
        lang
        pageUrl
        liveTime
        isLive
        companies {
          name
          squareLogoUrl
          id
        }
      }
    }
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment VideoPageContentQuery_1X4EH4 on Query {
  content(slug: $videoSlug, type: [VIDEO, WEBCAST]) {
    __typename
    id
    title
    slug
    lang
    htmlBody
    isPremium
    summary
    companies {
      viewerIsFollowing
      id
      name
      pageUrl
      defaultInstrument {
        id
        isin
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    createdAt
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    ... on Video {
      imgUrl
      videoEmbedUrl(location: "inderes")
      audioEmbedUrl
      registrationInfoHtml
      registrationUrl
      liveTime
    }
    ... on Webcast {
      imgUrl
      videoEmbedUrl(location: "inderes")
      registrationInfoHtml
      registrationUrl
      liveTime
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
  }
  ...LatestVideos_Videos
}


type

__typename

title

lang

htmlBody

isPremium

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

first

order

upcoming

edges

ExpreS2ion Biotech Holding

ExpreS2ion Biotechnologies expects to publish its full-year report for 2025 (Q4) on 19 February 2026. Later the same day at 09:30, the company’s management will present the results for the financial year, provide an update on business and pipeline developments, and follow up on recent company news in a live online event, which will conclude with a Q&A session.

You can already sign up for the event and submit your questions. You do not need to participate live in order to submit questions for the presentation. ExpreS2ion Biotechnologies expects to publish its full-year report for 2025 (Q4) on 19 February 2026. Later the same day at 09:30, the company&#x2019;s management will present the results for the financial year, provide an update on business and pipeline developments, and follow up on recent company news in a live online event, which will conclude with a Q&amp;A session. Since the publication of the Q3 2025 report, ExpreS2ion has reported updated immunogenicity data from the first three patients treated in the ongoing Phase I study of ES2B-C001, the company&#x2019;s HER2-targeted therapeutic breast cancer vaccine. The data showed induction of HER2-specific antibody responses in multiple patients, with levels significantly above baseline, as well as early indications that the immune response may be maintained over the observation period. While the dataset remains limited and exploratory, it contributes to the biological validation of the programme. At the same time, the independent Data Safety Monitoring Board has reviewed the safety data from the first dose cohort and recommended progression to the next dose level, marking an important operational milestone in the continued clinical development. In connection with the presentation, in addition to the review of the full-year results for 2025, focus is expected to be on the continued progress of the Phase I study, including next steps in dose escalation, anticipated clinical milestones, and the overall timeline for data generation in 2026. Investors will also have the opportunity to receive an update on the company&#x2019;s capital position and financial runway, as well as the status of platform and partner projects, including ongoing vaccine programmes within malaria and other infectious diseases. ExpreS2ion Biotechnologies is a Danish biotechnology company focused on the development of vaccines based on its proprietary ExpreS2 production platform in combination with AdaptVac&#x2019;s VLP technology. Disclaimer: HC Andersen Capital receives payment from ExpreS2ion Biotechnologies for a Corporate Visibility/Digital IR subscription agreement. Michael Friis, 10:41, 20/01-2026

HC Andersen Capital

ExpreS2ion Biotechnologies – Presentation of the 2025 Full-Year Report and Q&A

Recent videos